Fig. 1: Overall survival of study population. | npj Breast Cancer

Fig. 1: Overall survival of study population.

From: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Fig. 1: Overall survival of study population.The alternative text for this image may have been generated using AI.

A Kaplan–Meier curve of the time to treatment discontinuation (TTD) of anastase study population. Median TTD was 5.0 months (95%CI: 2.8–7.1). B Kaplan–Meier curve of the progression free survival (PFS) of anastase study population. Median PFS was 6.3 months (95%CI: 3.9–8.7). C Kaplan–Meier curve of the time to next treatment or death (TNT-D) of anastase study population: Median TNT-D was 8.1 months (95%CI: 5.5–10.7).

Back to article page